US 11,654,140 B2
Treatment of ocular inflammatory diseases using laquinimod
Joel Kaye, Netanya (IL); Hussein Hallak, East Jerusalem (IL); and Nora Tarcic, Modiin (IL)
Assigned to Active Biotech AB, Lund (SE)
Filed by Active Biotech AB, Lund (SE)
Filed on Nov. 17, 2017, as Appl. No. 15/816,402.
Application 15/816,402 is a continuation of application No. 15/670,684, filed on Aug. 7, 2017, abandoned.
Application 15/670,684 is a continuation of application No. 15/582,162, filed on Apr. 28, 2017, abandoned.
Application 15/582,162 is a continuation of application No. 13/909,403, filed on Jun. 4, 2013, abandoned.
Claims priority of provisional application 61/655,526, filed on Jun. 5, 2012.
Prior Publication US 2018/0071275 A1, Mar. 15, 2018
Int. Cl. A61K 31/4704 (2006.01); A61K 9/08 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/4704 (2013.01) [A61K 9/0048 (2013.01); A61K 9/0053 (2013.01); A61K 9/08 (2013.01)] 25 Claims
 
1. A method of treating a subject suffering from an ocular inflammatory disease, the method comprising periodic administration to the subject of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof effective to treat the subject, wherein the subject does not have Crohn's disease, and wherein the ocular inflammatory disease is uveitis.